Walter L. Vervenne

2.3k total citations · 2 hit papers
35 papers, 1.8k citations indexed

About

Walter L. Vervenne is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Walter L. Vervenne has authored 35 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 20 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Walter L. Vervenne's work include Pancreatic and Hepatic Oncology Research (13 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (8 papers). Walter L. Vervenne is often cited by papers focused on Pancreatic and Hepatic Oncology Research (13 papers), Cancer Genomics and Diagnostics (9 papers) and Renal cell carcinoma treatment (8 papers). Walter L. Vervenne collaborates with scholars based in Netherlands, Germany and United States. Walter L. Vervenne's co-authors include Chris Verslype, Yves Humblet, Eric Van Cutsem, Jan Cosaert, Jaafar Bennouna, Malcolm J. Moore, Jean‐Luc Van Laethem, Aijing Shang, Helmut Oettle and Werner Scheithauer and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and Annals of Oncology.

In The Last Decade

Walter L. Vervenne

34 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer

2004 616 citations Eric Van Cutsem, Helgi van de Velde et al. Journal of Clinical Oncology profile →
Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer

2009 504 citations Eric Van Cutsem, Walter L. Vervenne et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Walter L. Vervenne Netherlands	14	1.3k	729	561	530	322	35	1.8k
Carmelo Tibaldi Italy	20	1.5k 1.2×	991 1.4×	351 0.6×	604 1.1×	140 0.4×	73	2.1k
B. Massidda Italy	23	1.6k 1.3×	848 1.2×	662 1.2×	302 0.6×	292 0.9×	84	2.3k
Nobuyuki Mizunuma Japan	23	1.5k 1.2×	530 0.7×	367 0.7×	506 1.0×	259 0.8×	133	2.0k
Ellen Hollywood United States	17	1.3k 1.1×	419 0.6×	296 0.5×	462 0.9×	377 1.2×	33	1.7k
Kostas Kalbakis Greece	28	1.8k 1.4×	806 1.1×	708 1.3×	410 0.8×	232 0.7×	90	2.1k
Sebastiano Buti Italy	26	1.1k 0.9×	1.2k 1.6×	485 0.9×	690 1.3×	369 1.1×	210	2.2k
Jan Cosaert United States	17	1.1k 0.8×	644 0.9×	336 0.6×	438 0.8×	128 0.4×	43	1.5k
Luciano Burattini Italy	20	603 0.5×	626 0.9×	330 0.6×	493 0.9×	225 0.7×	55	1.3k
G. Frasci Italy	22	1.3k 1.1×	976 1.3×	315 0.6×	400 0.8×	178 0.6×	97	1.9k
Giulia Pasello Italy	23	1.1k 0.9×	1.1k 1.5×	349 0.6×	510 1.0×	151 0.5×	165	2.0k

Countries citing papers authored by Walter L. Vervenne

Since Specialization

Citations

This map shows the geographic impact of Walter L. Vervenne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walter L. Vervenne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walter L. Vervenne more than expected).

Fields of papers citing papers by Walter L. Vervenne

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walter L. Vervenne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walter L. Vervenne. The network helps show where Walter L. Vervenne may publish in the future.

Co-authorship network of co-authors of Walter L. Vervenne

This figure shows the co-authorship network connecting the top 25 collaborators of Walter L. Vervenne. A scholar is included among the top collaborators of Walter L. Vervenne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walter L. Vervenne. Walter L. Vervenne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vervenne, Walter L., Alexander L.T. Imholz, R.G.H.M. Cremers, et al.. (2023). Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clinical Pharmacokinetics. 62(7). 989–996. 3 indexed citations

Krens, Stefanie D., Frank G. A. Jansman, David M. Burger, et al.. (2021). The impact of a 1‐hour time interval between pazopanib and subsequent intake of gastric acid suppressants on pazopanib exposure. International Journal of Cancer. 148(11). 2799–2806. 12 indexed citations

Westgeest, Hans M., R. Jeroen A. van Moorselaar, Niven Mehra, et al.. (2020). Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. European Urology Focus. 7(4). 788–796. 3 indexed citations

Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2015). SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer. European Urology. 68(5). 837–847. 111 indexed citations

Michel, Maurice Stephan, Walter L. Vervenne, Maria De Santis, et al.. (2014). SWITCH: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 32(4_suppl). 393–393. 32 indexed citations

Eichelberg, Christian, Walter L. Vervenne, Maria De Santis, et al.. (2014). Updated Os Analysis, Multivariate and Qtwist Analysis of a Randomized Sequential Open-Label Study (Switch) to Evaluate Efficacy and Safety of Sorafenib (So) / Sunitinib (Su) Versus Su/So in the Treatment of Metastatic Renal Cell Cancer (Mrcc). Annals of Oncology. 25. iv290–iv290. 4 indexed citations

Goebell, Peter J., Walter L. Vervenne, Maria De Santis, et al.. (2014). Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).. Journal of Clinical Oncology. 32(15_suppl). 4567–4567. 9 indexed citations

Michel, Maurice Stephan, Walter L. Vervenne, Peter J. Goebell, et al.. (2012). Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis results.. Journal of Clinical Oncology. 30(15_suppl). 4539–4539. 8 indexed citations

Saif, Muhammad Wasif, Helmut Oettle, Walter L. Vervenne, et al.. (2009). Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas. The Cancer Journal. 15(4). 339–343. 44 indexed citations

10.

Verslype, Chris, Walter L. Vervenne, Jaafar Bennouna, et al.. (2009). Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. Journal of Clinical Oncology. 27(15_suppl). 4532–4532. 17 indexed citations

11.

Westerterp, Marinke, Marja A. Boermeester, Jikke M.T. Omloo, et al.. (2008). Differential responses of cellular immunity in patients undergoing neoadjuvant therapy followed by surgery for carcinoma of the oesophagus. Cancer Immunology Immunotherapy. 57(12). 1837–1847. 19 indexed citations

12.

Vervenne, Walter L., Jaafar Bennouna, Yves Humblet, et al.. (2008). A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer. Journal of Clinical Oncology. 26(15_suppl). 4507–4507. 38 indexed citations

13.

Hemert, Formijn J. van, et al.. (2006). Radiopharmaceutical management of90Y/111In labeled antibodies: shielding and quantification during preparation and administration. Annals of Nuclear Medicine. 20(8). 575–581. 4 indexed citations

14.

Westerterp, Marinke, Jikke M.T. Omloo, Gerrit W. Sloof, et al.. (2006). Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET. International Journal of Hyperthermia. 22(2). 149–160. 46 indexed citations

15.

Vervenne, Walter L., Marco J. Bruno, D. J. Gouma, et al.. (2005). Short intensive chemoradiation, 50 Gy/4 weeks with tegafur/uracil, leucovorin and celecoxib for non-metastatic locally advanced pancreatic cancer. Journal of Clinical Oncology. 23(16_suppl). 4191–4191. 1 indexed citations

16.

Richards, Donald, Helmut Oettle, Walter L. Vervenne, et al.. (2005). Randomized double-blind phase II trial comparing gemcitabine (GEM) plus LY293111 vs. GEM plus placebo in advanced adenocarcinoma of the pancreas. Journal of Clinical Oncology. 23(16_suppl). 4092–4092. 6 indexed citations

17.

Tienhoven, Geertjan van, Walter L. Vervenne, Saffire S.K.S. Phoa, et al.. (2004). High-dose conformal radiotherapy and concomitant 5-FU, followed by gemcitabine for non-metastatic unresectable pancreatic carcinoma: A phase II prospective study. Journal of Clinical Oncology. 22(14_suppl). 4181–4181. 1 indexed citations

18.

Vervenne, Walter L., J. Bollen, JJGHM Bergman, et al.. (2004). Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer. Journal of Clinical Oncology. 22(14_suppl). 4054–4054. 1 indexed citations

19.

Cutsem, Eric Van, Helgi van de Velde, Petr Karásek, et al.. (2004). Phase III Trial of Gemcitabine Plus Tipifarnib Compared With Gemcitabine Plus Placebo in Advanced Pancreatic Cancer. Journal of Clinical Oncology. 22(8). 1430–1438. 616 indexed citations breakdown →

20.

Richel, D. J. & Walter L. Vervenne. (2004). Systemic treatment of oesophageal cancer. European Journal of Gastroenterology & Hepatology. 16(3). 249–254. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact